Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
DEPEND is an open-label but dosage-masked trial of the retired cholesterol-lowering drug
probucol as an agent to increase availability of apolipoprotein E (apoE) in the cerebrospinal
fluid (CSF) of cognitively intact older persons at risk of Alzheimer's dementia. Absorption
of oral probucol is variable. In a sample of 23 cognitively intact persons over age 55,
DEPEND will therefore develop an algorithm to prescribe individualized dosing to achieve
plasma concentration that will likely increase availability of CSF apoE. These persons will
then use their individualized dosage for 12 months to assess longer-term effects of the drug
on CSF apoE concentration, while monitoring closely for evidence of adverse consequences of
use.